Merck stock trades on report context and market data
Published on 07/26/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. (ISIN US58933Y1055) is discussed here with the latest evidenced market and company figures available in this call, including a dated share-price context, recent revenue scale, and reported earnings metrics.
Revenue scale matters
Merck reported $64.2 billion in 2024 revenue, up 7% from 2023, with Keytruda continuing to anchor the companys top line. The same reporting cycle showed $0.53 in diluted EPS for 2024, a level that gives the stock a concrete profit baseline for comparison.
Margins and earnings
Operating performance also matters for valuation. Merck posted $20.6 billion in gross profit for 2024, and the company said R&D spending remained a major operating item as it advanced late-stage pipeline work.
Product mix and pipeline
Keytruda remains the most important product reference point, because Merck said the drug generated $29.5 billion in 2024 sales. That figure is larger than the companys 2023 total revenue from several single-product peers and underscores how concentrated the business still is around one oncology franchise.
Market context
Merck stock is priced in USD on the New York Stock Exchange, but no dated live quote is included in this call, so the article stays anchored to the companys latest evidenced operating numbers instead of an unverified intraday move.
Merck reporting context and product mix
The latest filing context highlights how revenue, EPS, and Keytruda sales shape the stock narrative.
Keytruda still dominates
Merck said Keytruda produced $29.5 billion in 2024 sales, which means the cancer drug remained the companys biggest commercial engine by a wide margin. That concentration is useful for investors because it links any future growth or slowdown directly to a single franchise rather than a broad product basket.
Stock and venue
Merck & Co. stock trades on the New York Stock Exchange in USD under the ticker NYSE: MRK. The companys 2024 figures - $64.2 billion in revenue, $0.53 diluted EPS, and $29.5 billion in Keytruda sales - are the main visible numbers available for framing the stock without relying on an unverified live quote.
Product line focus
Keytruda is the representative product line because it is the clearest single driver in Mercks 2024 mix. The drug remains central to any stock-level discussion because its $29.5 billion sales base is large enough to influence both growth expectations and the market view of concentration risk.
Closing price context
Merck stock is quoted in USD on the NYSE, and the article uses the latest evidenced annual reporting numbers rather than an unverified as-of quote. That keeps the stock note anchored to $64.2 billion revenue, $0.53 diluted EPS, and $29.5 billion Keytruda sales for 2024.
Merck & Co. stock facts
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: NYSE: MRK
- Trading venue: New York Stock Exchange
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Dow Jones Industrial Average
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
